Andrea Alimonti, Targeting MDSC for prostate cancer therapy
- Speaker: Andrea Alimonti, Group Leader, Molecular Oncology and Mouse Models, Institute of Oncology Research, Bellinzona, Switzerland
- Talk title: Targeting MDSC for prostate cancer therapy
- Date & time: Friday 18th September, 12:00h
- Host: Joaquin Mateo, Prostate Cancer Translational Research Group
The major scientific contributions of Prof. Alimonti research include the identification of the relevance of “quasi-insufficiency” in cancer initiation and the discovery of a novel pro-senescence approach to cancer therapy based on immunotherapy. Prof. Alimoti overall vision is to develop state-of-the-art innovative treatments for patients affected by cancer. Some of these treatments are currently tested in the clinic by Prof. Alimonti team.